Literature DB >> 17504018

Lysine-specific demethylase 1 as a potential therapeutic target.

Pete Stavropoulos1, André Hoelz.   

Abstract

Chromatin is a highly dynamic structure that undergoes a variety of chemical modifications. These modifications mediate alterations of the chromatin architecture, generate binding platforms that are recognized by other proteins, and are important elements of epigenetic gene regulation. An array of antagonizing histone modifying enzymes that catalyze the attachment and removal of a number of chemical groups has been described and their biologic role has been an intense area of research. With the recent discovery of the first histone demethylase, lysine-specific demethylase-1, a dynamic view of histone methylation was born. As a deeper understanding of their involvement in transcriptional regulation is gained, histone demethylases are becoming increasingly interesting targets for drug development.

Mesh:

Substances:

Year:  2007        PMID: 17504018     DOI: 10.1517/14728222.11.6.809

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  24 in total

1.  Cyclopropanamine Compounds and Use Thereof.

Authors:  Benjamin Blass
Journal:  ACS Med Chem Lett       Date:  2015-12-01       Impact factor: 4.345

Review 2.  Post-translational modifications of nucleosomal histones in oligodendrocyte lineage cells in development and disease.

Authors:  Siming Shen; Patrizia Casaccia-Bonnefil
Journal:  J Mol Neurosci       Date:  2008-05       Impact factor: 3.444

3.  Molecular basis for the autoregulation of the protein acetyl transferase Rtt109.

Authors:  Pete Stavropoulos; Vivien Nagy; Günter Blobel; André Hoelz
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-21       Impact factor: 11.205

Review 4.  Recent advances in the development of polyamine analogues as antitumor agents.

Authors:  Robert A Casero; Patrick M Woster
Journal:  J Med Chem       Date:  2009-08-13       Impact factor: 7.446

Review 5.  KDM1 class flavin-dependent protein lysine demethylases.

Authors:  Jonathan M Burg; Jennifer E Link; Brittany S Morgan; Frederick J Heller; Amanda E Hargrove; Dewey G McCafferty
Journal:  Biopolymers       Date:  2015-07       Impact factor: 2.505

6.  3,5-Diamino-1,2,4-triazoles as a novel scaffold for potent, reversible LSD1 (KDM1A) inhibitors.

Authors:  Craig J Kutz; Steven L Holshouser; Ethan A Marrow; Patrick M Woster
Journal:  Medchemcomm       Date:  2014-12       Impact factor: 3.597

Review 7.  Computational methods for de novo protein design and its applications to the human immunodeficiency virus 1, purine nucleoside phosphorylase, ubiquitin specific protease 7, and histone demethylases.

Authors:  M L Bellows; C A Floudas
Journal:  Curr Drug Targets       Date:  2010-03       Impact factor: 3.465

8.  New histone demethylase LSD1 inhibitor selectively targets teratocarcinoma and embryonic carcinoma cells.

Authors:  Nam Hoang; Xuan Zhang; Chunxiao Zhang; Van Vo; Feng Leng; Lovely Saxena; Feng Yin; Fei Lu; Guangrong Zheng; Pradip Bhowmik; Hui Zhang
Journal:  Bioorg Med Chem       Date:  2018-02-07       Impact factor: 3.641

Review 9.  Chromatin-modifying enzymes as therapeutic targets--Part 1.

Authors:  Brian R Keppler; Trevor K Archer
Journal:  Expert Opin Ther Targets       Date:  2008-10       Impact factor: 6.902

Review 10.  Polyamine analogues targeting epigenetic gene regulation.

Authors:  Yi Huang; Laurence J Marton; Patrick M Woster; Robert A Casero
Journal:  Essays Biochem       Date:  2009-11-04       Impact factor: 8.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.